Why Roche Holding Stock Popped Today
Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib drug for treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Image source: Getty Images.
Conducted over more than 96 weeks, the first trial "significantly reduced the annualized relapse rate (ARR) compared to teriflunomide," an RMS drug developed by Sanofi and currently available as a generic from multiple manufacturers.
Source Fool.com
Roche Holding AG ADR Stock
Our community is currently high on Roche Holding AG ADR with 4 Buy predictions and 2 Sell predictions.
With a target price of 46 € there is a slightly positive potential of 8.0% for Roche Holding AG ADR compared to the current price of 42.59 €.


